SARASOTA, FL -- (MARKET WIRE) -- 11/21/2005 -- DNAPrint™ genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that Khandaker Partners, an independent research and advisory firm specializing in small cap and emerging growth companies, has prepared a research report on the Company and its technology.

Included in the report is a comprehensive interview with Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer, and Richard Gabriel, President and Chief Executive Officer, who lay out their vision for the DNAPrint genomics' future.

The report, which was paid for by the Company, can be accessed online at www.dnaprint.com or at http://www.khandaker.com/index.cfm?page=viewcompany&CoID=879#analyst_report .

Copies of the report can be obtained by emailing rripatti@khandaker.com.

About DNAPrint

DNAPrint genomics, Inc. (www.dnaprint.com), through its DNAPrint Pharmaceutics, Inc., wholly owned subsidiary, is a developer of genomics-based products and services focused on drug development, computational biology and pharmacogenomic diagnostic tests. Computational biology and pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint also develops and markets products for the law enforcement forensics and consumer markets that include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Richard Gabriel
President and CEO
941-366-3400

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848